Dr Arndt Schottelius to lead Kymab’s R&D

Cambridge, UK-based Kymab has appointed Dr Arndt Schottelius to the newly-created position of executive vice president of research and development.

Dr Schottelius will take on responsibility for the human monoclonal antibody specialist's R&D activities, including pre-clinical and clinical developments, from May this year.

He joins from MorphoSys, where he has been chief development officer since 2008, overseeing a portfolio of therapeutic antibody programmes in oncology and immunology.

Previously, Dr Schottelius was medical director of immunology development at Genentech based in San Francisco, US, and held scientific and management positions in immunology research at Berlex Biosciences in California, US and Schering AG in Berlin, Germany.

Dr David Chiswell, chief executive of Kymab, said: “I am delighted to welcome Dr Schottelius to the Kymab team.

“His strong management expertise developed at both MorphoSys AG and Genentech as well as his unique experience and track record in drug development supports our commitment to pursue the opportunities in our R&D programmes following our recent $100m Series C funding.

“Dr Schottelius' appointment validates the current strength and exciting potential of our growing product pipeline.”